Cathepsin cysteine protease inhibitors

Details for Australian Patent Application No. 2005203820 (hide)

Owner Merck Frosst Canada Ltd.

Inventors Crane, Sheldon N.; Leger, Serge; Bayly, Christopher

Agent Spruson & Ferguson

Pub. Number AU-A-2005203820

PCT Pub. Number WO2005/065778

Priority 60/535,170 08.01.04 US

Filing date 6 January 2005

Wipo publication date 21 July 2005

International Classifications

A61P 19/08 (2006.01) Drugs for skeletal disorders

C07D 207/26 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 307/33 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Event Publications

13 July 2006 PCT application entered the National Phase

  PCT publication WO2005/065778 Priority application(s): WO2005/065778

29 July 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005203822-Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in combination therapies for the treatment of cancer

2005203816-Gaming apparatus and systems